Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress (StockTitan.net) - Sep 23, 2026 - "The company will deliver a late‑breaker oral presentation on October 1, 2026 at 5:00pm CEST in Hall A, covering week‑16 efficacy and safety results of abdakibart (ABD) from the placebo‑controlled Phase 2 LOTUS trial, including IHS4 subgroup and lesion type ANdT analyses. A poster presentation on September 30, 2026 at 7:00am CEST in the ePoster Area (Inflammatory Skin Diseases – Part II) will report primary results of the same Phase 2 LOTUS trial."
Late-breaking abstract • P2 data • Hidradenitis Suppurativa
|